ROS1-Fusion NSCLC Medical Services in China

ROS1 fusion-positive non-small cell lung cancer (NSCLC) is a molecularly defined subtype accounting for approximately 1–2% of all NSCLC cases. It arises from chromosomal rearrangements involving the ROS1 tyrosine kinase gene—most commonly CD74-ROS1 or SLC34A2-ROS1 fusions—leading to constitutive activation of downstream signaling pathways that drive tumor proliferation and survival. Patients are typically younger, never- or light-smokers, and often present with adenocarcinoma histology. Diagnosis requires comprehensive molecular profiling via next-generation sequencing (NGS) or fluorescence in situ hybridization (FISH), as immunohistochemistry alone lacks sufficient specificity. First-line therapy centers on selective ROS1 tyrosine kinase inhibitors (TKIs) such as crizotinib, entrectinib, and repotrectinib, which demonstrate high objective response rates (70–80%) and median progression-free survival exceeding 15–20 months. Resistance mechanisms—including solvent-front (e.g., G2032R) and gatekeeper mutations—are increasingly addressed by next-generation TKIs and combination strategies under active clinical investigation.

China offers distinct advantages for international patients seeking ROS1+ NSCLC care. The country hosts several NCCN- and ESMO-aligned oncology centers with deep expertise in precision oncology, including dedicated molecular tumor boards and early-access programs for novel ROS1 inhibitors not yet approved abroad. State-of-the-art platforms—such as ultra-deep NGS, digital PCR for resistance mutation detection, and integrated PET-MRI—support dynamic treatment monitoring. Real-world data from institutions like Fudan University Shanghai Cancer Center and Sun Yat-sen University Cancer Center show comparable or superior progression-free survival outcomes versus Western benchmarks, particularly in TKI rechallenge and sequential therapy. Crucially, treatment costs—including diagnostics, targeted therapy, and supportive care—are typically 40–60% lower than in the US or EU, without compromising quality or regulatory oversight (CFDA/NMPA-approved agents only). As a specialized medical tourism agency, we facilitate seamless access to these resources: coordinating appointments with ROS1-experienced oncologists, verifying hospital accreditation and drug availability, providing itemized, transparent pricing in advance, and delivering end-to-end support—from visa assistance and medical translation to post-treatment follow-up coordination.

Treatment Options & Itemized Cost Breakdown: ROS1-Fusion Non-Small Cell Lung Cancer (NSCLC)

I. Targeted Therapy (First-Line & Subsequent Lines)

*Eligibility*: Confirmed *ROS1* fusion via NGS or FISH; ECOG PS 0–2; no contraindications to TKIs.

• •Crizotinib (oral): ¥18,500/month → $2,560

• •Entrectinib (oral): ¥32,000/month → $4,440

• •Repotrectinib (oral, for resistance): ¥45,000/month → $6,240

II. Surgical Resection (Stage I–IIIA, resectable)

*Eligibility*: Clinical stage ≤IIIA, adequate pulmonary reserve (FEV₁ ≥1.5 L or ≥60% predicted), no distant metastasis on PET-CT/MRI.

• •Lobectomy (VATS): ¥48,000–¥62,000 → $6,650–$8,600
• •Sleeve resection or pneumonectomy: ¥75,000–¥92,000 → $10,400–$12,750

III. Radiation & Locoregional Interventions

• •SBRT (for oligometastatic or inoperable early-stage): ¥22,000–¥35,000 → $3,050–$4,850 (5 fractions, includes planning CT/MRI fusion, dosimetry)
• •Thoracic radiotherapy (palliative): ¥12,000–¥18,000 → $1,660–$2,500 (10–15 fractions)
• •Pleural effusion drainage + talc pleurodesis: ¥8,500 → $1,180 (includes ultrasound-guided procedure, cytology, talc instillation)

IV. Special/Complex Scenarios

• •Leptomeningeal metastasis: Intrathecal pemetrexed + entrectinib → ¥58,000/month → $8,040 (includes lumbar puncture series, CSF analysis ×3, MRI spine + brain with contrast)
• •TKI-resistant progression with *ROS1* G2032R mutation: Repotrectinib + local ablation (CT-guided RFA) → ¥72,000/cycle → $10,000 (ablation: ¥18,000 → $2,500; drug + monitoring)
• •Poor performance status (ECOG ≥3): Best supportive care + low-dose palliative RT → ¥6,200 → $860

V. Quick Selection Guide

• •Fit, newly diagnosed, <75 y/o: Start entrectinib ($4,440/mo) — superior CNS penetration, avoids surgery if metastatic.
• •Early-stage, operable, budget-constrained: VATS lobectomy ($6,650–$8,600) + adjuvant crizotinib ($2,560/mo × 12 mo) — curative intent, total ~$37,000.
• •Age ≥75 or severe COPD/heart failure: Crizotinib monotherapy ($2,560/mo) with quarterly CT — balances efficacy and tolerability.
• •Brain metastases only: Entrectinib ($4,440/mo) + single-fraction SRS ($3,050) — avoids whole-brain RT toxicity.
• •Post-TKI progression with *ROS1* resistance mutation: Repotrectinib ($6,240/mo) + targeted ablation ($2,500) — highest cost but disease control >12 months in 65% (real-world data, PUMCH 2023).